Literature DB >> 27889902

Establishment and characterization of a novel uterine carcinosarcoma cell line, TU-ECS-1, with mutations of TP53 and KRAS.

Yohei Chiba1, Seiya Sato1, Hiroaki Itamochi2, Yasuko Suga1, Tomoyuki Fukagawa1,3, Nao Oumi4, Tetsuro Oishi4, Tasuku Harada4, Tamotsu Sugai3, Toru Sugiyama1.   

Abstract

A new human uterine carcinosarcoma (UCS) cell line, TU-ECS-1, was established and characterized. The morphological appearance of the cultured cells was an insular of epithelial-like cells arranged in the form of a jigsaw puzzle and mesenchymal-like cells with a spindle-shaped or fibroblast-like morphology. A relatively high proliferation rate was observed with a doubling time of 18.2 h. The chromosome number ranged from 44 to 49 and had an extra chromosome 12 (trisomy 12). The respective half-maximal inhibitory concentrations of cisplatin, paclitaxel, and doxorubicin were 2.9 µM, 154 nM, and 219 ng/mL, respectively. Mutational analysis revealed that TU-ECS-1 cells have mutations of TP53 in exons 4, 6, and 8 and of KRAS at codon 12 (G12D) in exon 2, which is a mutation hot spot on this gene. Western blot analysis showed that p53 protein was overexpressed in TU-ECS-1 cells. Immunostaining of the cultured cells and in vivo tumors showed that the TU-ECS-1 cells and xenografts were positive for epithelial marker cytokeratin AE1/3 and mesenchymal marker vimentin. These results suggested that TU-ECS-1 cells might have both epithelial and mesenchymal characteristics. This cell line may be useful to study the carcinogenesis of UCS and contribute to the development of novel treatment strategies.

Entities:  

Keywords:  Establishment; KRAS; Molecular-targeted therapy; TP53; Uterine carcinosarcoma

Mesh:

Substances:

Year:  2016        PMID: 27889902     DOI: 10.1007/s13577-016-0154-6

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  35 in total

Review 1.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

Review 2.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.

Authors:  Jeffrey A Engelman; Ji Luo; Lewis C Cantley
Journal:  Nat Rev Genet       Date:  2006-08       Impact factor: 53.242

3.  Tetrasomy 12 in ovarian tumors of thecoma-fibroma group: A fluorescence in situ hybridization analysis using paraffin sections.

Authors:  S B Liang; H Sonobe; T Taguchi; T Takeuchi; M Furihata; K Yuri; Y Ohtsuki
Journal:  Pathol Int       Date:  2001-01       Impact factor: 2.534

4.  Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases.

Authors:  S G Silverberg; F J Major; J A Blessing; B Fetter; F B Askin; S Y Liao; A Miller
Journal:  Int J Gynecol Pathol       Date:  1990       Impact factor: 2.762

Review 5.  Uterine carcinosarcoma: A review of the literature.

Authors:  Leigh A Cantrell; Stephanie V Blank; Linda R Duska
Journal:  Gynecol Oncol       Date:  2015-03-21       Impact factor: 5.482

6.  Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.

Authors:  Howard D Homesley; Virginia Filiaci; Maurie Markman; Pincas Bitterman; Lynne Eaton; Larry C Kilgore; Bradley J Monk; Frederick R Ueland
Journal:  J Clin Oncol       Date:  2007-02-10       Impact factor: 44.544

Review 7.  The management of patients with uterine sarcoma: a debated clinical challenge.

Authors:  Angiolo Gadducci; Stefania Cosio; Antonella Romanini; Andrea Riccardo Genazzani
Journal:  Crit Rev Oncol Hematol       Date:  2007-08-13       Impact factor: 6.312

8.  A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas.

Authors:  G A Omura; F J Major; J A Blessing; T V Sedlacek; J T Thigpen; W T Creasman; R J Zaino
Journal:  Cancer       Date:  1983-08-15       Impact factor: 6.860

9.  The impact of multi-modal therapy on survival for uterine carcinosarcomas.

Authors:  Jesus Gonzalez Bosquet; Shelby A Terstriep; William A Cliby; Monica Brown-Jones; Judith S Kaur; Karl C Podratz; Gary L Keeney
Journal:  Gynecol Oncol       Date:  2009-11-05       Impact factor: 5.304

10.  Mutational landscape and significance across 12 major cancer types.

Authors:  Cyriac Kandoth; Michael D McLellan; Fabio Vandin; Kai Ye; Beifang Niu; Charles Lu; Mingchao Xie; Qunyuan Zhang; Joshua F McMichael; Matthew A Wyczalkowski; Mark D M Leiserson; Christopher A Miller; John S Welch; Matthew J Walter; Michael C Wendl; Timothy J Ley; Richard K Wilson; Benjamin J Raphael; Li Ding
Journal:  Nature       Date:  2013-10-17       Impact factor: 49.962

View more
  2 in total

Review 1.  True hypopharyngeal carcinosarcoma: a case report and literature review.

Authors:  Jiang-Tao Zhong; Xiao-Xing Xie; Shui-Hong Zhou; Hong-Tian Yao; Zhe Chen; Ting-Ting Wu; Yang-Yang Bao; Qi Yu; He-Ming Han
Journal:  J Int Med Res       Date:  2018-07-12       Impact factor: 1.671

2.  HDAC Inhibition Induces Cell Cycle Arrest and Mesenchymal-Epithelial Transition in a Novel Pleural-Effusion Derived Uterine Carcinosarcoma Cell Line.

Authors:  Paul Stockhammer; Özlem Okumus; Luca Hegedus; Dominika Rittler; Till Ploenes; Thomas Herold; Stavros Kalbourtzis; Agnes Bankfalvi; Antje Sucker; Rainer Kimmig; Clemens Aigner; Balazs Hegedus
Journal:  Pathol Oncol Res       Date:  2021-03-26       Impact factor: 3.201

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.